Epi-Drugs in Heart Failure
Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes)...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.923014/full |
| _version_ | 1828764054414426112 |
|---|---|
| author | Era Gorica Era Gorica Shafeeq A. Mohammed Samuele Ambrosini Vincenzo Calderone Sarah Costantino Sarah Costantino Francesco Paneni Francesco Paneni Francesco Paneni |
| author_facet | Era Gorica Era Gorica Shafeeq A. Mohammed Samuele Ambrosini Vincenzo Calderone Sarah Costantino Sarah Costantino Francesco Paneni Francesco Paneni Francesco Paneni |
| author_sort | Era Gorica |
| collection | DOAJ |
| description | Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure. |
| first_indexed | 2024-12-11T02:13:41Z |
| format | Article |
| id | doaj.art-e10a86f66f0b416f91dd75e3cd256ab7 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-11T02:13:41Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-e10a86f66f0b416f91dd75e3cd256ab72022-12-22T01:24:14ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-07-01910.3389/fcvm.2022.923014923014Epi-Drugs in Heart FailureEra Gorica0Era Gorica1Shafeeq A. Mohammed2Samuele Ambrosini3Vincenzo Calderone4Sarah Costantino5Sarah Costantino6Francesco Paneni7Francesco Paneni8Francesco Paneni9Center for Molecular Cardiology, University of Zürich, Schlieren, SwitzerlandDepartment of Pharmacy, University of Pisa, Pisa, ItalyCenter for Molecular Cardiology, University of Zürich, Schlieren, SwitzerlandCenter for Molecular Cardiology, University of Zürich, Schlieren, SwitzerlandDepartment of Pharmacy, University of Pisa, Pisa, ItalyCenter for Molecular Cardiology, University of Zürich, Schlieren, SwitzerlandDepartment of Cardiology, University Heart Center, Zurich, SwitzerlandCenter for Molecular Cardiology, University of Zürich, Schlieren, SwitzerlandDepartment of Cardiology, University Heart Center, Zurich, SwitzerlandDepartment of Research and Education, University Hospital Zurich, Zurich, SwitzerlandUnveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure.https://www.frontiersin.org/articles/10.3389/fcvm.2022.923014/fullepigeneticscardiovascular diseasesepi-drugsheart failurenon-coding RNAs |
| spellingShingle | Era Gorica Era Gorica Shafeeq A. Mohammed Samuele Ambrosini Vincenzo Calderone Sarah Costantino Sarah Costantino Francesco Paneni Francesco Paneni Francesco Paneni Epi-Drugs in Heart Failure Frontiers in Cardiovascular Medicine epigenetics cardiovascular diseases epi-drugs heart failure non-coding RNAs |
| title | Epi-Drugs in Heart Failure |
| title_full | Epi-Drugs in Heart Failure |
| title_fullStr | Epi-Drugs in Heart Failure |
| title_full_unstemmed | Epi-Drugs in Heart Failure |
| title_short | Epi-Drugs in Heart Failure |
| title_sort | epi drugs in heart failure |
| topic | epigenetics cardiovascular diseases epi-drugs heart failure non-coding RNAs |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.923014/full |
| work_keys_str_mv | AT eragorica epidrugsinheartfailure AT eragorica epidrugsinheartfailure AT shafeeqamohammed epidrugsinheartfailure AT samueleambrosini epidrugsinheartfailure AT vincenzocalderone epidrugsinheartfailure AT sarahcostantino epidrugsinheartfailure AT sarahcostantino epidrugsinheartfailure AT francescopaneni epidrugsinheartfailure AT francescopaneni epidrugsinheartfailure AT francescopaneni epidrugsinheartfailure |